2,238 results on '"RCC"'
Search Results
2. A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)
- Published
- 2024
3. Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy (REVOLUTION)
- Published
- 2024
4. A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors (SPX-303)
- Published
- 2024
5. Prognostic Factors and Treatment Outcomes in Renal Cell Carcinoma: A Comprehensive Analysis.
- Author
-
ELÇİÇEK, Ömer Faruk and KÜÇÜKÖNER, Mehmet
- Subjects
CANCER relapse ,ACADEMIC medical centers ,PROTEIN-tyrosine kinase inhibitors ,KARNOFSKY Performance Status ,TREATMENT effectiveness ,CANCER patients ,CHI-squared test ,DESCRIPTIVE statistics ,KAPLAN-Meier estimator ,RENAL cell carcinoma ,DRUG efficacy ,PROGRESSION-free survival ,DATA analysis software ,CONFIDENCE intervals ,OVERALL survival ,PHARMACODYNAMICS ,DISEASE risk factors - Abstract
Copyright of Namık Kemal Tıp Dergisi is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
6. TFE3‐rearranged nonmelanotic renal PEComa: a case series expanding their phenotypic and fusion landscape.
- Author
-
Agaimy, Abbas, Acosta, Andres M, Cheng, Liang, Collins, Katrina, Fridman, Eddie, Schubart, Christoph, Williamson, Sean R, Hartmann, Arndt, and Trpkov, Kiril
- Subjects
- *
FLUORESCENCE in situ hybridization , *TUBEROUS sclerosis , *RENAL cell carcinoma , *GENE fusion , *PATIENTS - Abstract
Aims Methods and Results Conclusion A subset of exceptionally rare primary renal perivascular epithelioid cell tumours (PEComas) that harbour Xp11.2 translocation have been reported, but no larger series devoted to this topic have been published.We describe the clinicopathological and molecular features of 10 renal PEComas, collected from our routine and consultation files. There were five female and five male patients aged 14–65 (median: 32 years). One patient had a history of childhood neuroblastoma, but no patients were known to have a tuberous sclerosis complex or other hereditary disorder. Complete surgical excision was the treatment for all patients. The available follow‐up in five patients indicated a favourable outcome in 4/5 cases. Tumour size ranged from 2.8 to 15.2 cm (median, 5.2 cm). Immunohistochemistry revealed consistently strong TFE3 expression in all tumours, whereas PAX8 and keratin cocktails were uniformly negative. Other positive markers included HMB45 (7/9 tumours), CathepsinK (7/9 tumours), and CD117 (KIT) (3/5 tumours). TFE3 rearrangements were detected in 8/9 tumours (by targeted RNA sequencing in seven and by FISH in one). The identified fusion partners included SFPQ (n = 2) and one tumour each with ASPSCR1, ZC3H4, MED15, RBMX, and PRCC. One tumour that lacked TFE3 rearrangement by next‐generation sequencing (NGS) and fluorescence in situ hybridization (FISH) revealed a large intrachromosomal deletion involving PKD1 and TSC2 by DNA‐based NGS.This study highlights the morphologic and genetic diversity of TFE3‐rearranged primary renal PEComas and underlines the value of surrogate TFE3 immunohistochemistry in identifying them. The lack of PAX8 and keratin expression represents the mainstay for distinguishing these tumours from MiTF‐associated renal cell carcinomas. In addition, we report rare (ZC3H4, RBMX) and novel (MED15) TFE3 fusion partners in PEComa. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Mapping of Human Polyomavirus in Renal Cell Carcinoma Tissues.
- Author
-
Mobaraki, Ghalib, Shi, Shuai, Liu, Dan, Smits, Kim M., Severens, Kim, Lommen, Kim, Rennspiess, Dorit, Speel, Ernst-Jan M., Winnepenninckx, Véronique, Klufah, Faisal, Samarska, Iryna, and Hausen, Axel zur
- Subjects
- *
RENAL cell carcinoma , *MERKEL cells , *DNA viruses , *GENE expression , *POLYOMAVIRUSES - Abstract
Worldwide, the incidence of renal cell carcinoma (RCC) is rising, accounting for approximately 2% of all cancer diagnoses and deaths. The etiology of RCC is still obscure. Here, we assessed the presence of HPyVs in paraffin-embedded tissue (FFPE) resected tissue from patients with RCC by using different molecular techniques. Fifty-five FFPE tissues from 11 RCC patients were included in this study. Consensus and HPyV-specific primers were used to screen for HPyVs. Both PCR approaches revealed that HPyV is frequently detected in the tissues of RCC kidney resections. A total of 78% (43/55) of the tissues tested were positive for at least one HPyV (i.e., MCPyV, HPyV6, HPyV7, BKPyV, JCPyV, or WUyV). Additionally, 25 tissues (45%) were positive for only one HPyV, 14 (25%) for two HPyVs, 3 (5%) for three HPyVs, and 1 one (1%) tissue specimen was positive for four HPyVs. Eleven (20%) RCC specimens were completely devoid of HPyV sequences. MCPyV was found in 24/55 RCC tissues, HPyV7 in 19, and HPyV6 in 8. The presence of MCPyV and HPyV6 was confirmed by specific FISH or RNA-ISH. In addition, we aimed to confirm HPyV gene expression by IHC. Our results strongly indicate that these HPyVs infect RCC and nontumor tissues, possibly indicating that kidney tissues serve as a reservoir for HPyV latency. Whether HPyVs possibly contribute to the etiopathogenesis of RCC remains to be elucidated. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Analysis of Mechanical Properties of Fiber Reinforced Concrete Using RCC and PCC.
- Author
-
Fan, Jiawei, Long, Yiyu, Xu, Juntao, Qiu, Shumao, and Qiao, Wei
- Subjects
ROLLER compacted concrete ,FIBER-reinforced concrete ,SYNTHETIC fibers ,FLEXURAL strength ,CRACKING of concrete ,CONCRETE pavements - Abstract
The addition of macro fibers to concrete pavements has been used to improve the cracking of concrete pavement, reduce slab thickness and contribute to increasing the joint spacing. A laboratory test was carried out in the study to analyze the impact of fiber reinforced concrete (FRC) on plain cement concrete (PCC) and roller compacted concrete (RCC), determining the flexural strength by performing ASTM-1609 tests and compressive strength by ASTM C-39 tests. Two synthetic fiber types selected with different geometries and different dosages (0.25% and 0.5% by volume) were tested for both RCC and PCC. To examine the effect of fiber contents and property, statistical testing was done using strength-test data. The test result showed that flexural strength was not affected by fibers. As fiber content increased, both residual strength (F
600 and F150 ) and specimen toughness (T150 ) increased for each fiber type. To the contrary, the compressive strength of specimens with higher fiber contents was lower in every case. Fiber properties including length and shape affected the residual strength of RCC more, than PCC. It is notable that the residual strength of RCC and PCC with the same fiber condition is very similar, even though the mix design and compressive and flexural strengths are different. In this paper, the strength-test data results are discussed, and the factors affecting the test results and the limitations of the testing methods are suggested. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
9. PDIA4 在肾癌细胞舒尼替尼耐药中的作用研究.
- Author
-
唐麒麟, 柯波亮, 何雏江, 徐子杰, 陈 磊, and 邵 怡
- Subjects
- *
RENAL cell carcinoma , *PROTEIN disulfide isomerase , *RENAL cancer , *CANCER cell proliferation , *SUNITINIB - Abstract
Objective: To establish a renal cell carcinoma sunitinib-resistant cell line and to explore the mechanism by which protein disulfide isomerase A4 (PDIA4) regulates sunitinib resistance in renal cell carcinoma. Methods: A small-dose intermittent induction method was used to establish 786-O and OS-RC-2 resistant cell lines (786-OR and OS-RC-2R), qRT-PCR and Western blot were used to detect the expression of PDIA4 in drug-resistant renal carcinoma cell lines and non-drug-resistant renal carcinoma cell lines, and lentiviral infection was used to construct a stable overexpression or knockdown renal carcinoma cell line of PDIA4. The effect of PDIA4 on the proliferation of renal cancer cells was detected by CCK-8 assay; the expression of apoptosis-related proteins BCL2, BAX, Caspase3, Cleaved-Caspase3, and Caspase9 was detected by RT-qPCR and Western blot. Results: Compared with the control group of parental cells 786-O and OS-RC-2, the PDIA4 expression levels of drug-resistant cell lines 786-OR and OS-RC-2R are significantly increased (P<0.05). Overexpression of PDIA4 promoted the growth and viability of renal cancer cells as well as decreased the sensitivity of renal cancer cells to sunitinib (P<0.05), whereas knockdown of PDIA4 inhibited the growth and viability of renal cancer cells as well as elevated the sensitivity of renal cancer cells to sunitinib (P<0.05). In addition, overexpression of PDIA4 inhibited the expression of pro-apoptotic proteins (P<0.05), while knockdown of PDIA4 promoted the expression of pro-apoptotic proteins (P<0.05). Conclusion: PDIA4 is associated with sunitinib resistance in renal cell carcinoma by the mechanism of inhibition of apoptosis causing sunitinib resistance in renal cell carcinoma, and targeting PDIA4 reverses the resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Carrying Capacity Assessment in Complex Systems: A Comprehensive Revisit with Enhanced Elements.
- Author
-
Joseph, Sindhu and P., Mahadevan
- Subjects
SUSTAINABILITY ,SUSTAINABLE tourism ,CORRECTION factors ,EVIDENCE gaps ,SUSTAINABLE development - Abstract
The rapid growth of tourism necessitates sustainable resource management and effective strategies to ensure sustainable development and minimize detrimental impacts on destinations. By synthesizing existing research, this article contributes to a holistic understanding of Tourism Carrying Capacity (TCC) and its various components, aiding policymakers, planners, and stakeholders in making informed decisions for sustainable development. This research reviews CC assessment methods and formulas, focusing on Physical Carrying Capacity (PCC), Effective Carrying Capacity (ECC), and Real Carrying Capacity (RCC). Moreover, this study delves into the evolving notion of limiting factors, examining how factors such as infrastructure, resource availability, socio-cultural aspects, and environmental resilience interact to determine carrying capacity thresholds in various research realms. By synthesizing existing methodologies and formulas, this research bridges the gap between theoretical frameworks and practical implementation, fostering sustainable tourism practices that preserve natural and cultural assets while fostering economic growth. This work further advances the existing formula for TCC calculation in complex systems by providing a fresh set of correction factors (Cf) and Management capacities (Mc) and providing all possible values for calculating space for the displacement(V/A) of tourists in different types of destinations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. An Application of Deep Learning Using Leaky Rectified Linear Unit and Hyperbolic Tangent in Non-destructive Testing
- Author
-
Tekwani, Bharti, Gupta, Archana Bohra, Bansal, Jagdish Chand, Series Editor, Deep, Kusum, Series Editor, Nagar, Atulya K., Series Editor, Tiwari, Ritu, editor, Saraswat, Mukesh, editor, and Pavone, Mario, editor
- Published
- 2024
- Full Text
- View/download PDF
12. An Intelligent Model to Predict the Compactness of Granular Mixtures Used in Conventional (CC) and Roller-Compacted Concrete (RCC)
- Author
-
Sadok, Ahmed Hadj, Chakali, Youcef, Tahlaiti, Mahfoud, Ali, Mohamed Mohamed, Pisello, Anna Laura, Editorial Board Member, Hawkes, Dean, Editorial Board Member, Bougdah, Hocine, Editorial Board Member, Rosso, Federica, Editorial Board Member, Abdalla, Hassan, Editorial Board Member, Boemi, Sofia-Natalia, Editorial Board Member, Mohareb, Nabil, Editorial Board Member, Mesbah Elkaffas, Saleh, Editorial Board Member, Bozonnet, Emmanuel, Editorial Board Member, Pignatta, Gloria, Editorial Board Member, Mahgoub, Yasser, Editorial Board Member, De Bonis, Luciano, Editorial Board Member, Kostopoulou, Stella, Editorial Board Member, Pradhan, Biswajeet, Editorial Board Member, Abdul Mannan, Md., Editorial Board Member, Alalouch, Chaham, Editorial Board Member, Gawad, Iman O., Editorial Board Member, Nayyar, Anand, Editorial Board Member, Amer, Mourad, Series Editor, Çiner, Attila, editor, Ergüler, Zeynal Abiddin, editor, Bezzeghoud, Mourad, editor, Ustuner, Mustafa, editor, Eshagh, Mehdi, editor, El-Askary, Hesham, editor, Biswas, Arkoprovo, editor, Gasperini, Luca, editor, Hinzen, Klaus-Günter, editor, Karakus, Murat, editor, Comina, Cesare, editor, Karrech, Ali, editor, Polonia, Alina, editor, and Chaminé, Helder I., editor
- Published
- 2024
- Full Text
- View/download PDF
13. CircPRELID2 functions as a promoter of renal cell carcinoma through the miR-22-3p/ETV1 cascade
- Author
-
Xi Lin and Yi Zhi
- Subjects
RCC ,circPRELID2 ,miR-22-3p ,ETV1 expression ,Malignant progression ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Abstract Background Emerging evidence has indicated that a number of circular RNAs (circRNAs) participate in renal cell carcinoma (RCC) carcinogenesis. Nevertheless, the activity and molecular process of circPRELID2 (hsa_circ_0006528) in RCC progression remain unknown. Methods CircPRELID2, miR-22-3p and ETS variant 1 (ETV1) levels were gauged by qRT-PCR. Effect of the circPRELID2/miR-22-3p/ETV1 axis was evaluated by detecting cell growth, motility, and invasion. Immunoblotting assessed related protein levels. The relationships of circPRELID2/miR-22-3p and miR-22-3p/ETV1 were confirmed by RNA immunoprecipitation (RIP), luciferase reporter or RNA pull-down assay. Results CircPRELID2 was up-regulated in RCC. CircPRELID2 silencing suppressed RCC cell growth, motility and invasion. Moreover, circPRELID2 silencing weakened M2-type macrophage polarization in THP1-induced macrophage cells. CircPRELID2 sequestered miR-22-3p, and circPRELID2 increased ETV1 expression through miR-22-3p. Moreover, the inhibitory impact of circPRELID2 silencing on RCC cell malignant behaviors was mediated by the miR-22-3p/ETV1 axis. Furthermore, circPRELID2 knockdown in vivo hampered growth of xenograft tumors. Conclusion Our study demonstrates that circPRELID2 silencing can mitigate RCC malignant development through the circPRELID2/miR-22-3p/ETV1 axis, highlighting new therapeutic targets for RCC treatment.
- Published
- 2024
- Full Text
- View/download PDF
14. Interaction of immune cells with renal cancer development: Mendelian randomization (MR) study
- Author
-
Zhongwen Lu, Yu Yin, Tian Rao, Xinchi Xu, Kai Zhao, Zhanpeng Liu, Chao Qin, and Min Tang
- Subjects
RCC ,Mendelian randomization ,Immune cells ,Tumor microenvironment ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Renal cell carcinoma (RCC) is a prevalent and extensively immune-infiltrated malignancy of the urinary system. Immune cells play a crucial role in both the progression and therapeutic interventions targeting RCC. Nevertheless, the interplay between RCC and immune cells remains understudied, lacking substantial evidence supporting their causal relationship. Methods For the purpose of investigating the causal connection between RCC and immune cell characteristics, a two-way two-sample Mendelian randomization (MR) analysis was carried out in this study. The aim was to determine whether specific immune cell traits have a causal impact on the risk of RCC. In order to achieve this, publicly accessible genetic data was utilized to examine and establish the potential relationship between 731 immune cell characteristics and the likelihood of developing RCC. Additionally, various techniques were applied to verify the reliability, variability, and presence of horizontal pleiotropy in the outcomes. Results We found a bidirectional causal relationship between RCC and immune cells according to the MR analysis results. It should be noted that CD4-CD8-T cells (OR = 1.61, 95%CI = 1.02–2.55, P = 4.07 × 10–2) pose a risk for RCC, whereas BAFF-R (OR = 0.69, 95%CI = 0.53–0.89, P = 5.74 × 10–3) and CD19 (OR = 0.59, 95%CI = 1.02–2.55, P = 4.07 × 10–2) on B cells act as protective factors. Furthermore, the presence of RCC reduces the levels of B cells (OR = 1.05, 95%CI = 1.01–1.09, P = 1.19 × 10–2) and CD8 + T cells (OR = 1.04, 95%CI = 1.00–1.08, P = 2.83 × 10–2). Conclusions Our research illustrates the intricate correlation between immune cells and RCC, presenting novel insights for the prospective safeguarding against RCC risk and the exploration of fresh therapeutic targets.
- Published
- 2024
- Full Text
- View/download PDF
15. Paraneoplastic NMDA encephalitis, a case report and an extensive review of available literature
- Author
-
Hamza Alzghoul, MD, Ferdous Kadri, MD, Mohamed F. Ismail, MD, Robeer Youssef, Mustafa Shamaileh, MD, Ahmad R. Al-Assi, Liliya Adzhieva, MD, and Bashar Alzghoul, MD
- Subjects
NMDAr encephalitis ,Paraneoplastic ,Renal cell carcinoma ,RCC ,Radiology ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Anti-N-methyl-D-aspartate receptor (NMDAr) encephalitis is a prevalent autoimmune condition marked by diverse neuropsychiatric symptoms, primarily impacting young females. The exact mechanisms underlying the development of NMDAr encephalitis have not been fully elucidated. Nonetheless, studies have demonstrated that auto-antibodies targeting the NR1-NR2 subunits of the NMDAr can trigger receptor dysfunction within the central nervous system, thus giving rise to the associated symptoms. Notably, an association exists between NMDAr encephalitis and an underlying neoplastic condition, with approximately 38% of cases exhibiting this paraneoplastic relationship with ovarian teratomas being the most commonly associated malignancy.While the association between NMDAr encephalitis and renal cell carcinoma (RCC) is exceedingly rare. This case report presents the clinical scenario of a 20-year-old female patient diagnosed with NMDAr encephalitis in conjunction with RCC discovered incidentally on a CT abdomen and pelvis performed to rule out an ovarian teratoma. The presented case underscores the importance of adopting a multidisciplinary approach in the diagnosis and treatment of NMDAr encephalitis, particularly when it is linked to an underlying malignancy. Furthermore, it emphasizes the significance of expanding our understanding of the molecular pathogenesis of NMDAr encephalitis to enhance patient care and optimize clinical outcomes. Additionally, a comprehensive review of the existing literature is included, summarizing all reported malignancies associated with NMDAr encephalitis.
- Published
- 2024
- Full Text
- View/download PDF
16. Clear Cell Renal Cell Carcinoma With Syncytial-Type Multinucleated Giant Tumor Cells: A Clinicopathologic Study of 14 Cases.
- Author
-
Nova-Camacho, Luiz M. and Sangoi, Ankur R.
- Subjects
- *
MULTINUCLEATED giant cells , *GIANT cell tumors , *RENAL cell carcinoma , *CHORIONIC gonadotropins , *CLINICAL pathology , *BREAST - Abstract
The presence of syncytial-type multinucleated giant tumor cells with emperipolesis in clear cell renal cell carcinoma (RCC) is uncommon, with only 31 cumulative published cases to date. After a rereview of 125 clear cell RCC of World Health Organization/International Society of Urological Pathology grade 3 or 4, 14 clear cell RCCs with admixed syncytial-type giant cells (to our knowledge, the largest series to date) were found with a mean patient age of 67 years and with no sex difference (M = 7, F = 7). Mean tumor size was 7.3 cm. The syncytial-type giant cells comprised between 2% and 20% of the tumor and were present mainly around areas of necrosis. Five tumors were staged as pT1 or pT2, 8 as pT3, and 1 as pT4. Other findings included sarcomatoid differentiation (3/14), rhabdoid differentiation (4/14), and emperipolesis (12/14). Positive immunostains included keratin AE1/AE3 (13/13), carbonic anhydrase 9 and CD10 (12/14 each), vimentin (8/14), EMA (5/12), and alpha-methyacyl-CoA racemase (3/12). Keratin 7, keratin 20, human melanoma black 45, KIT, TFE3, cathepsin K, CD68, CD61, and beta human chorionic gonadotropin were negative. Six of 13 patients had recurrence or metastases during a mean follow-up time of 56 months. Four of 13 patients died of disease, 2 of 13 patients were alive with the disease, and 7 of 13 patients had no evidence of disease. Although the incidence of finding syncytial-type multinucleated giant tumor cells in clear cell RCC is low (approximately 1.2%), given that a subset of the patients showed poor outcomes while lacking other poor histologic parameters (eg, sarcomatoid or rhabdoid differentiation), it may be prudent to recognize and report this feature when encountered. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Low-grade oncocytic tumor: a review of radiologic and clinical features.
- Author
-
Chai, Jessie L., Siegmund, Stephanie E., Hirsch, Michelle S., and Silverman, Stuart G.
- Subjects
- *
ELECTRONIC health records , *SYMPTOMS , *WATCHFUL waiting , *TUMORS - Abstract
Purpose: The 2022 World Health Organization classification of renal neoplasia expanded the spectrum of oncocytic neoplasms to encompass newly established and emerging entities; one of the latter is the low-grade oncocytic tumor (LOT). This study reports the radiologic appearance and clinical behavior of LOT. Methods: In this IRB-approved, HIPPA-compliant retrospective study, our institution's pathology database was searched for low-grade oncocytic tumors or neoplasms. Patient age, gender, and comorbidities were obtained from a review of electronic medical records, and imaging characteristics of the tumors were assessed through an imaging platform. Results: The pathology database search yielded 14 tumors in 14 patients. Four patients were excluded, as radiologic images were not available in three, and one did not fulfill diagnostic criteria after pathology re-review. The resulting cohort consisted of 10 tumors (median diameter 2.3 cm, range 0.7–5.1) in 10 patients (median age 68 years, range 53–91, six women). All tumors presented as a solitary, well-circumscribed, mass with solid components. All enhanced as much or almost as much as adjacent renal parenchyma; all but one enhanced heterogeneously. None had lymphadenopathy, venous invasion, or metastatic disease at presentation or at clinical follow-up (median, 22.2 months, range 3.4–71.6). Among five tumors undergoing active surveillance, mean increase in size was 0.4 cm/year at imaging follow-up (median 16.7 months, range 8.9–25.4). Conclusion: LOT, a recently described pathologic entity in the kidney, can be considered in the differential diagnosis of an avidly and typically heterogeneously enhancing solid renal mass in an adult patient. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. A Novel Technique for Hand-Assisted Laparoscopy in Difficult Nephrectomies—Is One Hand Better Than Two? A Single-Centre, Single-Surgeon Series.
- Author
-
Ram, Prasanna, Das, Manoj K., Mandal, Swarnendu, Nayak, Prasant, and Tripathy, Sambit
- Abstract
Laparoscopic radical nephrectomy is the standard of care for T1 renal tumors and nowadays being used for T2 or higher tumors, resulting in higher the conversion rates. To bridge this gap, the hand-assisted laparoscopy (HAL) method was introduced. Even now, in the robotic era, this HAL approach continues to find importance in urology, especially in the most challenging cases, albeit, with a relatively low usage rate due to the cost involved and availability of hand port devices. Here, we report a case series using a novel modification of the HAL nephrectomy (HALN) technique when open conversion is needed. From a prospective database, we retrospectively analyzed the data of Six patients who underwent HALN at the All India Institute of Medical Sciences between January 2019 and December 2022. Indications for surgery included both malignant and benign renal disease. Four surgeries were performed on the right side while two were performed on the left. Five patients underwent a HALN for renal cell carcinoma (RCC) and 1 for a benign non-functioning kidney. In our series, all the cases with RCC had were T2a or higher. Our case series shows that HALN is technically safe, effective, and a great adjunct to conventional laparoscopy. The ingenious use of a surgical glove as a hand port is an easy-to-make-and- use device in such challenging surgeries. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Magnetic-Resonance-Imaging-Guided Cryoablation for Solitary-Biopsy-Proven Renal Cell Carcinoma: A Tertiary Cancer Center Experience.
- Author
-
Abdelsalam, Mohamed E., Mecci, Nabeel, Awad, Ahmed, Bassett, Roland L., Odisio, Bruno C., Habibollahi, Peiman, Lu, Thomas, Irwin, David, Karam, Jose A., Matin, Surena F., and Ahrar, Kamran
- Subjects
- *
BIOPSY , *SURVIVAL rate , *CANCER relapse , *RESEARCH funding , *MAGNETIC resonance imaging , *CRYOSURGERY , *TREATMENT effectiveness , *CANCER patients , *TERTIARY care , *DESCRIPTIVE statistics , *RETROSPECTIVE studies , *RADIO frequency therapy , *RENAL cell carcinoma , *COMPARATIVE studies , *CATHETER ablation - Abstract
Simple Summary: The aim is to evaluate the long-term efficacy and survival outcome of MRI-guided cryoablation of small renal masses. Our renal ablation database was reviewed. We concluded that MRI-guided cryoablation is a very effective treatment for small kidney masses with long-term disease control. Background: Our purpose is to evaluate the long-term oncologic efficacy and survival rates of MRI-guided cryoablation for patients with biopsy-proven cT1a renal cell carcinoma (RCC). Materials and Methods: We retrospectively reviewed our renal ablation database between January 2007 and June 2021 and only included patients with solitary-biopsy-proven cT1a RCC (≤4 cm) who underwent MRI-guided cryoablation. We excluded patients with genetic syndromes, bilateral RCC, recurrent RCC or benign lesions, those without pathologically proven RCC lesions and patients who underwent radiofrequency ablation or CT-guided cryoablation. For each patient, we collected the following: age, sex, lesion size, right- or left-sided, pathology, ablation zone tumor recurrence, development of new tumor in the kidney other than ablation zone, development of metastatic disease, patient alive or not, date and cause of death. We used the Kaplan and Meier product limit estimator to estimate the survival outcomes. Results: Twenty-nine patients (median age 70 years) met our inclusion criteria. Twenty-nine MRI-guided cryoablation procedures were performed for twenty-nine tumor lesions with a median size of 2.2 cm. A Clavien–Dindo grade III complication developed in one patient (3.4%). Clear cell RCC was the most reported histology (n = 19). The median follow up was 4.5 years. No tumor recurrence or metastatic disease developed in any of the patients. Two patients developed new renal lesions separate from the ablation zone. The 5- and 10-year OS were 72% and 55.6%, respectively. The 5- and 10-year DFS were 90.5% and the 5-year and 10-year LRFS, MFS and CSS were all 100%. Conclusions: MRI-guided cryoablation is a safe treatment with a low complication rate. Long-term follow-up data revealed long-standing oncologic control. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. CircPRELID2 functions as a promoter of renal cell carcinoma through the miR-22-3p/ETV1 cascade.
- Author
-
Lin, Xi and Zhi, Yi
- Subjects
RENAL cell carcinoma ,CIRCULAR RNA ,CELL growth ,CANCER cells ,PHENOTYPES - Abstract
Background: Emerging evidence has indicated that a number of circular RNAs (circRNAs) participate in renal cell carcinoma (RCC) carcinogenesis. Nevertheless, the activity and molecular process of circPRELID2 (hsa_circ_0006528) in RCC progression remain unknown. Methods: CircPRELID2, miR-22-3p and ETS variant 1 (ETV1) levels were gauged by qRT-PCR. Effect of the circPRELID2/miR-22-3p/ETV1 axis was evaluated by detecting cell growth, motility, and invasion. Immunoblotting assessed related protein levels. The relationships of circPRELID2/miR-22-3p and miR-22-3p/ETV1 were confirmed by RNA immunoprecipitation (RIP), luciferase reporter or RNA pull-down assay. Results: CircPRELID2 was up-regulated in RCC. CircPRELID2 silencing suppressed RCC cell growth, motility and invasion. Moreover, circPRELID2 silencing weakened M2-type macrophage polarization in THP1-induced macrophage cells. CircPRELID2 sequestered miR-22-3p, and circPRELID2 increased ETV1 expression through miR-22-3p. Moreover, the inhibitory impact of circPRELID2 silencing on RCC cell malignant behaviors was mediated by the miR-22-3p/ETV1 axis. Furthermore, circPRELID2 knockdown in vivo hampered growth of xenograft tumors. Conclusion: Our study demonstrates that circPRELID2 silencing can mitigate RCC malignant development through the circPRELID2/miR-22-3p/ETV1 axis, highlighting new therapeutic targets for RCC treatment. Highlights: (1) CircPRELID2 silencing impacts RCC cell phenotypes. (2) CircPRELID2 sequesters miR-22-3p. (3) CircPRELID2 increases ETV1 expression through miR-22-3p. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Genetic variants in the mTOR pathway with renal cancer risk and subtypes in East Indian population.
- Author
-
Malakar, Subhajit, Chatterjee, Srilagna, Das, Madhusudhan, and Pal, Dilip Kumar
- Subjects
- *
RENAL cancer , *GENETIC variation , *DISEASE risk factors , *RENAL cell carcinoma , *DNA sequencing , *NUCLEIC acid isolation methods - Abstract
Introduction: Renal Cell Carcinoma (RCC), which accounts for 2%–3% of all adult malignant neoplasms with a male-to-female predominance of 1.9 to 1 with typical presentation between 55 and 75 years. The phosphoinositide-3-kinase–protein kinase B/Akt (PI3KPKB/Akt) pathway is a main pathway in control of cell growth. mTOR pathway plays a key role in the pathogenesis of RCC. Material and methods: Its a prospective observational study. Tissue samples were collected and processed and DNA isolation and sequencing was done to see for any association and expression. Results and analysis: Polymorphism analysis of the sequence of three genes MTOR, AKT1, and PIK3CA done and found an intronic variant of the MTOR gene (rs3737611) and AKT1 gene (rs2498797) to be significantly associated with clear cell Renal Cell Carcinoma tumor samples. Discussion: This study will help to understand the pathogenesis better and the information can be used to develop new drugs and personalized treatment strategies that are tailored to an individual's genetic makeup. The study identify individuals who are at heightened risk for developing renal cancer and could benefit from targeted screening or preventative measures. Some sample size and definite geographical sample pool remains the main limitation of the study which may not be externally validate the study results. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Kafa Karıştırıcı 1: Bosniak v2019 Işığında Renal Kistik Lezyonların Değerlendirilmesi.
- Author
-
Seyrek, Sinan, Dağoğlu Kartal, Merve Gülbiz, and Apaydın, Feramuz Demir
- Subjects
RENAL cancer ,SENSITIVITY & specificity (Statistics) ,CYSTS (Pathology) ,CLASSIFICATION ,UROLOGY - Abstract
Copyright of Türk Radyoloji Seminerleri is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
23. Disparities in Trend of Renal Cell Carcinoma Mortality in the United States.
- Author
-
DODDI, SISHIR and RASHID, M. HAMMAD
- Subjects
RENAL cell carcinoma ,RACE ,ASIANS ,KIDNEY pelvis ,MORTALITY - Abstract
Background/Aim: Renal cell carcinoma (RCC) accounts for 90% of malignant neoplasms of the kidney. Patients and Methods: In this report, the CDC WONDER database was accessed to retrieve age-adjusted mortality data from 1999 to 2020 due to RCC, defined as ICD-10 Code: C64 Malignant neoplasm of kidney except renal pelvis, for various demographics to investigate trends and potential disparities. Results: In 2020, the overall ageadjusted mortality rate (AAMR) due to RCC in the USA was 42.4 per 1,000,000. The average annual percent change (AAPC) for the USA from 1999 to 2020 was -0.6%. Notably, in 2020, men had a higher AAMR than women, 63.9 compared to 25.7, and a significant difference in AAPC trend was identified between men (-0.5%) and women (-1.0%). When investigating trends according to race in 2020, the Asian population displayed the lowest AAMR at 18.9. When determining AAPC from 1999 to 2020 according to race group, the American Indian group demonstrated the greatest decline in AAPC at -1.3%, followed by the Black (-1.2%) and White populations (-0.5%). The Asian population did not exhibit a significant AAPC. Moreover, the rates between these three groups were statistically significantly differentindicating disparities in trend based on race. Conclusion: This investigation assesses the AAMR for different demographic groups of the USA population to identify disparities and guide resource allocation strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Interaction of immune cells with renal cancer development: Mendelian randomization (MR) study.
- Author
-
Lu, Zhongwen, Yin, Yu, Rao, Tian, Xu, Xinchi, Zhao, Kai, Liu, Zhanpeng, Qin, Chao, and Tang, Min
- Subjects
- *
RENAL cancer , *CARCINOGENESIS , *CANCER cells , *RENAL cell carcinoma , *B cells - Abstract
Background: Renal cell carcinoma (RCC) is a prevalent and extensively immune-infiltrated malignancy of the urinary system. Immune cells play a crucial role in both the progression and therapeutic interventions targeting RCC. Nevertheless, the interplay between RCC and immune cells remains understudied, lacking substantial evidence supporting their causal relationship. Methods: For the purpose of investigating the causal connection between RCC and immune cell characteristics, a two-way two-sample Mendelian randomization (MR) analysis was carried out in this study. The aim was to determine whether specific immune cell traits have a causal impact on the risk of RCC. In order to achieve this, publicly accessible genetic data was utilized to examine and establish the potential relationship between 731 immune cell characteristics and the likelihood of developing RCC. Additionally, various techniques were applied to verify the reliability, variability, and presence of horizontal pleiotropy in the outcomes. Results: We found a bidirectional causal relationship between RCC and immune cells according to the MR analysis results. It should be noted that CD4-CD8-T cells (OR = 1.61, 95%CI = 1.02–2.55, P = 4.07 × 10–2) pose a risk for RCC, whereas BAFF-R (OR = 0.69, 95%CI = 0.53–0.89, P = 5.74 × 10–3) and CD19 (OR = 0.59, 95%CI = 1.02–2.55, P = 4.07 × 10–2) on B cells act as protective factors. Furthermore, the presence of RCC reduces the levels of B cells (OR = 1.05, 95%CI = 1.01–1.09, P = 1.19 × 10–2) and CD8 + T cells (OR = 1.04, 95%CI = 1.00–1.08, P = 2.83 × 10–2). Conclusions: Our research illustrates the intricate correlation between immune cells and RCC, presenting novel insights for the prospective safeguarding against RCC risk and the exploration of fresh therapeutic targets. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. A pilot study of [68Ga]Ga-fibroblast activation protein inhibitor-04 PET/CT in renal cell carcinoma.
- Author
-
Guo, Chunmei, Liu, Ya, Yang, Haozhou, Xia, Yuxiao, Li, Xue, Chen, Liming, Feng, Yue, Zhang, Yan, Chen, Yue, and Huang, Zhanwen
- Subjects
- *
RENAL cell carcinoma , *POSITRON emission tomography , *LYMPHATIC metastasis , *BONE metastasis , *PILOT projects - Abstract
Objectives As a promising positron emission tomography (PET) tracer, [68Ga]Ga-fibroblast activation protein inhibitor-04([68Ga]Ga-FAPI-04) performs better than 2-[18F]fluoro-2-deoxy- d -glucose ([18F]FDG) at diagnosing primary and metastatic lesions in patients with various types of cancer. We investigated the utility of [68Ga]Ga-FAPI-04 PET/CT for the detection of primary and metastatic lesions in renal cell carcinoma (RCC). [18F]FDG PET/CT were used for comparison. Methods Twenty-two patients with suspected RCC or recurrent RCC were enrolled in our study. Among these patients, 14 were newly diagnosed with RCC, 3 had recurrent RCC, and 5 were excluded from further analysis due to having benign renal tumours. Seventeen patients with RCC underwent [68Ga]Ga-FAPI-04 PET/CT, and 6 of them also received [18F]FDG PET/CT. The positive detection rates were calculated and compared with those in patients who underwent both scans. Results Data from 17 patients with RCC (median age: 60.5 years, interquartile range [IQR]: 54-70 years) were evaluated. The positive detection rate of [68Ga]Ga-FAPI-04 PET/CT for RCC was 64.7% (11/17). Lymph node metastases (n = 44), lung metastasis (n = 1), and bone metastasis (n = 1) were detected. Six patients with RCC underwent [68Ga]Ga-FAPI-04 and [18F]FDG PET/CT. [68Ga]Ga-FAPI-04 PET/CT showed a higher positive detection rate than [18F]FDG PET/CT in detecting RCC (83.3% [5/6] vs. 50% [3/6], P = 0.545). Additionally, [68Ga]Ga-FAPI-04 PET/CT has higher SUVmax (3.20 [IQR: 2.91-5.80 vs. 2.71 [IQR: 2.13-3.10], P = 0.116) and tumour-to-background ratio (TBR) values (1.60 [IQR: 1.33-3.67] vs. 0.86 [0.48-1.21], P = 0.028) than [18F]FDG PET/CT. Conclusions These findings suggest that [68Ga]Ga-FAPI-04 PET/CT has potential value in RCC diagnosis. Further studies are warranted to validate these results. Advances in knowledge Clinical utility of [68Ga]Ga-FAPI-04 in RCC remains unclear, and there are not many similar studies in the literature. We evaluated the role of [68Ga]Ga-FAPI-04 in diagnosing RCC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Ablative Treatments for Small Renal Masses and Management of Recurrences: A Comprehensive Review.
- Author
-
Aveta, Achille, Iossa, Vincenzo, Spena, Gianluca, Conforti, Paolo, Pagano, Giovanni, Dinacci, Fabrizio, Verze, Paolo, Manfredi, Celeste, Ferro, Matteo, Lasorsa, Francesco, Spirito, Lorenzo, Napolitano, Luigi, Tufano, Antonio, Fiorenza, Alessandra, Russo, Pierluigi, Crocerossa, Fabio, Lucarelli, Giuseppe, Perdonà, Sisto, Sanseverino, Roberto, and Siracusano, Salvatore
- Subjects
- *
CONTRAST-enhanced ultrasound , *LITERATURE reviews , *WATCHFUL waiting , *CATHETER ablation , *CRYOSURGERY , *CARBON dioxide lasers - Abstract
This review focuses on ablative techniques for small renal masses (SRMs), including radiofrequency ablation (RFA), cryoablation (CA), microwave ablation (MWA), and irreversible electroporation (IRE), and discusses recurrence management. Through an extensive literature review, we outline the procedures, outcomes, and follow-up strategies associated with each ablative method. The review provides a detailed examination of these techniques—RFA, CA, MWA, and IRE—elucidating their respective outcomes. Recurrence rates vary among them, with RFA and CA showing comparable rates, MWA demonstrating favorable short-term results, and IRE exhibiting promise in experimental stages. For managing recurrences, various strategies are considered, including active surveillance, re-ablation, or salvage surgery. Surveillance is preferred post-RFA and post-CA, due to slow SRM growth, while re-ablation, particularly with RFA and CA, is deemed feasible without additional complications. Salvage surgery emerges as a viable option for larger or resistant tumors. While ablative techniques offer short-term results comparable to surgery, further research is essential to understand their long-term effects fully. Decisions concerning recurrence management should consider individual and tumor-specific factors. Imaging, notably contrast-enhanced ultrasounds, plays a pivotal role in assessing treatment success, emphasizing the necessity of a multidisciplinary approach for optimal outcomes. The lack of randomized trials highlights the need for further research. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Married Status Affects Rates of Treatment and Mortality in Male and Female Renal Cell Carcinoma Patients Across all Stages.
- Author
-
Siech, Carolin, Morra, Simone, Scheipner, Lukas, Baudo, Andrea, Jannello, Letizia M. I., de Angelis, Mario, Goyal, Jordan A., Zhe Tian, Saad, Fred, Shariat, Shahrokh F., Longo, Nicola, Carmignani, Luca, de Cobelli, Ottavio, Ahyai, Sascha, Briganti, Alberto, Mandel, Philipp, Kluth, Luis A., Chun, Felix K. H., and Karakiewicz, Pierre I.
- Subjects
- *
RENAL cell carcinoma , *CANCER-related mortality , *NEPHRECTOMY , *MARITAL status , *EPIDEMIOLOGY of cancer - Abstract
In stage-specific analyses of 98,142 renal cell carcinoma patients, married status independently predicted higher nephrectomy rates in males and females. In stage IV, married status predicted higher systemic therapy rate in males, but not in females. Married males exhibited lower cancer specific mortality across all stages; married females only in stages I and III (all P ≤ .02). Introduction: The association between treatment rates and cancer specific mortality (CSM) according to married status in male and female clear cell renal cell carcinoma (ccRCC) patients across all stages is unknown. Patient and Methods: Using the Surveillance, Epidemiology, and End Results database (2004-2020), ccRCC patients were stratified according to married status (married vs. unmarried). Logistic regression models addressed treatment rates; Cox regression models addressed CSM rates. Results: Of 98,142 patients, 43,999 (72%) males and 20,287 (55%) females were married. In stage-specific analyses, married status independently predicted higher nephrectomy rates in males and females (all P ≤ .03). In stage IV, married status predicted higher systemic therapy rate in males (P < .001), but not in females. In survival analyses, married males exhibited lower CSM rates relative to unmarried males (all P ≤ .02). Conversely, married females exhibited lower CSM rates only in stages I and III (all P ≤ .02), but not in stages II and IV. In subgroup analyses of T1aN0M0 patients, married status was associated with higher partial nephrectomy rates in both males and females (all P ≤ .005). Conclusion: In ccRCC, married status invariably predicts higher rates of guideline recommended surgical management (nephrectomy and partial nephrectomy). Moreover, even after adjustment for treatment type, married status independently predicted lower CSM rates in males across all stages. However, the effect of married status in females is only operational in stages I and III. Lack of association between married status in stages II and IV may potentially be explained by stronger association with treatment assignment which reduces the residual effect on survival. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Prognostic Significance of Radiographic Lymph Node Invasion in Contemporary Metastatic Renal Cell Carcinoma Patients.
- Author
-
Scheipner, Lukas, Incesu, Reha-Baris, Morra, Simone, Baudo, Andrea, Assad, Anis, Jannello, Letizia Maria Ippolita, Siech, Carolin, de Angelis, Mario, Zhe Tian, Saad, Fred, Shariat, Shahrokh F., Briganti, Alberto, Chun, Felix K. H., Tilki, Derya, Longo, Nicola, Carmignani, Luca, De Cobelli, Ottavio, Pichler, Martin, Ahyai, Sascha, and Karakiewicz, Pierre I.
- Subjects
- *
RENAL cell carcinoma , *LYMPHATIC metastasis , *CANCER-related mortality , *NEPHRECTOMY , *MEDICAL statistics - Abstract
We tested for the prognostic significante of radiographic N-stage in metastatic renal cell carcinoma (mRCC) patients with low metastatic burden (single metastatic site). After multivariable adjustment, radiographic N1 status was an independent predictor of higher cancer-specific mortality (CSM). In consequence, consideration of radiographic lymph node invasion might be of great value in this specific population of mRCC patients. Purpose: To test the prognostic significance of radiographic cN-stage in metastatic renal cell carcinoma (mRCC) patients with low metastatic burden (1 site of metastasis), relying on the Surveillance, Epidemiology, and End Results database (SEER 2010-2020). Methods: Included were mRCC patients with 1 site of metastasis, treated with systemic therapy without cytoreductive nephrectomy (CN). Kaplan-Meier plots and multivariable Cox-regression models addressed cancer-specific mortality (CSM) according to radiographic cN-stage (ccN1 vs. ccN0). Separate subgroup analyses were performed, addressing radiographic N-stage in patients with distinct histology (clear-cell vs. RCC not otherwise specified [RCC NOS]). Results: Of 1756 mRCC patients, 545 (31%) were radiographic cN1. Overall, the median CSM-free survival of the cohort was 11 months. Median CSM-free survival was 8 vs. 14 months in radiographic cN1 vs. cN0 mRCC patients (HR 1.49, P < .0001). In multivariable Cox regression analyses, radiographic cN1 status was an independent predictor of higher CSM (HR 1.39; P = .01). In subgroup analyses, addressing patients with clear-cell histology and patients with RCC NOS separately, radiographic cN1 status remained independently associated with a higher CSM in both groups (clear-cell: HR 1.36; P = .03; RCC NOS: HR 2.06; P = .009). Conclusion: In mRCC patients with low metastatic burden, presence or absence of radiographic lymph node invasion results in a clinically meaningful discrimination between those with poor prognosis and others. In consequence, consideration of radiographic lymph node invasion might be of great value in this specific population of mRCC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. PD-L1 as a Urine Biomarker in Renal Cell Carcinoma—A Case Series and Proof-of-Concept Study.
- Author
-
Reimold, Philipp, Tosev, Georgi, Kaczorowski, Adam, Friedhoff, Jana, Schwab, Constantin, Schütz, Viktoria, Görtz, Magdalena, Panzer, Niklas, Heller, Martina, Aksoy, Cem, Himmelsbach, Ruth, Walle, Thomas, Zschäbitz, Stefanie, Jäger, Dirk, Duensing, Anette, Stenzinger, Albrecht, Hohenfellner, Markus, and Duensing, Stefan
- Subjects
- *
PROGRAMMED death-ligand 1 , *BIOMARKERS , *URINE , *PROOF of concept , *IMMUNE checkpoint inhibitors - Abstract
Background: Renal cell carcinoma (RCC) is among the most lethal urologic malignancies once metastatic. Current treatment approaches for metastatic RCC (mRCC) involve immune checkpoint inhibitors (ICIs) that target the PD-L1/PD-1 axis. High PD-L1 expression in tumor tissue has been identified as a negative prognostic factor in RCC. However, the role of PD-L1 as a liquid biomarker has not yet been fully explored. Herein, we analyze urine levels of PD-L1 in mRCC patients before and after either ICI therapy or surgical intervention, as well as in a series of patients with treatment-naïve RCC. Patients and Methods: The mid-stream urine of patients with mRCC (n = 4) or treatment-naïve RCC, i.e., prior to surgery from two centers (cohort I, n = 49: cohort II, n = 29) was analyzed for PD-L1 by ELISA. The results from cohort I were compared to a control group consisting of patients treated for non-malignant urologic diseases (n = 31). In the mRCC group, urine PD-L1 levels were measured before and after tumor nephrectomy (n = 1) or before and after ICI therapy (n = 3). Exosomal PD-L1 in the urine was analyzed in selected patients by immunoblotting. Results: A strong decrease in urine PD-L1 levels was found after tumor nephrectomy or following systemic treatment with ICIs. In patients with treatment-naïve RCC (cohort I), urine PD-L1 levels were significantly elevated in the RCC group in comparison to the control group (median 59 pg/mL vs. 25.7 pg/mL, p = 0.011). PD-L1 urine levels were found to be elevated, in particular, in low-grade RCCs in cohorts I and II. Exosomal PD-L1 was detected in the urine of a subset of patients. Conclusion: In this proof-of-concept study, we show that PD-L1 can be detected in the urine of RCC patients. Urine PD-L1 levels were found to correlate with the treatment response in mRCC patients and were significantly elevated in treatment-naïve RCC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. STRESS AND STRAIN OF RCC PAVEMENT WITH CEMENT STABILIZED BASE DEPENDING ON LOAD AND SEASON OF THE YEAR.
- Author
-
MICKEVIČ, RAFAL and VAITKUS, AUDRIUS
- Subjects
ROLLER compacted concrete ,STRAIN gages ,PAVEMENTS ,STRAIN sensors ,CONCRETE mixing ,CONCRETE pavements - Abstract
Slip-form concrete (JPCP) has a number of years of good performance experience. An alternative to slip-form concrete is roller-compacted concrete (RCC). The RCC mixture has a significantly larger number of fine aggregates, which leads the concrete mix to be non-slip and compacted by rollers. RCC has the strength and performance of conventional concrete or even higher. Due to all the advantages, the use of RCC pavement in industrial areas and low-volume rural roads is very beneficial. Experimental test section of RCC pavement structure with cement and special additives stabilized base (CTB) was installed on local road No. 130 in Lithuania, which was reconstructed in 2021. The main objective of this study is to learn about the environmental impact on the pavement structure. To reach our aim at the stage of reconstruction of the local road temperature, humidity sensors and a strain gauge were installed under the RCC layer and CTB. During the lifetime of pavement structure temperature and humidity data were collected daily and bearing capacity was measured during spring thaw. In addition, an artificial wheel load simulation using a falling weight deflectometer was performed at the location of the installed strain gauge to analyse deflections and to calculate stresses under RCC layer. The stresses under the RCC layer calculated from the strain gauge were also compared with the theoretical stress calculated at the design stage of the pavement structure. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Percutaneous Image-Guided Cryoablation of Endophytic Renal Cell Carcinoma.
- Author
-
Jensen, Christian Greve, Dybdahl, Marco, Valtersson, John, Mussmann, Bo Redder, Duus, Louise Aarup, Junker, Theresa, Pietersen, Pia Iben, Lund, Lars, Welch, Brian T., and Graumann, Ole
- Subjects
CRYOSURGERY ,RENAL cancer ,COMORBIDITY ,NEPHRECTOMY - Abstract
Purpose: Endophytic renal cancer treatment is a challenge. Due to difficulties in endophytic tumor visualization during surgical extirpation, image-guided percutaneous cryoablation (PCA) is an attractive alternative. The minimally invasive nature of PCA makes it favorable for comorbid patients as well as patients in which surgery is contraindicated. Oncological outcomes and complications after PCA of endophytic biopsy-proven renal cell carcinoma (RCC) were reviewed in this study. Materials and Methods: Patients were included after a multidisciplinary team conference from January 2015 to November 2021. Inclusion criteria were endophytic biopsy-proven T1 RCC treated with PCA with one year of follow-up. Complications were reported according to the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) classification system and the Clavien-Dindo classification (CDC) system. Major complications were defined as a grade ≥ 3 according to the CDC. Results: Fifty-six patients were included with a total of 56 endophytic tumors treated during 61 PCA sessions. The median RENAL nephrometry score was 9 (IQR 2), and the mean tumor size was 25.7 mm (SD ± 8.9 mm). Mean hospitalization time was 0.39 (SD ± 1.1) days. At a mean follow-up of 996 days (SD ± 559), 86% of tumors were recurrence free after one PCA. No patients progressed to metastatic disease. According to the CIRSE classification, 10.7% (n = 6) had grade 3 complications, and 5.4% (n = 3) had CDC major complications. Conclusion: This study demonstrates that PCA of endophytic biopsy-proven T1 RCC is safe with few major complications and excellent local tumor control rates at almost three-year mean follow-up. Level of Evidence 3: Retrospective cohort study. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Role of clinicopathological variables in predicting recurrence and survival outcomes after surgery for non‐metastatic renal cell carcinoma: Systematic review and meta‐analysis.
- Author
-
Majdoub, Muhammad, Yanagisawa, Takafumi, Quhal, Fahad, Laukhtina, Ekaterina, von Deimling, Markus, Kawada, Tatsushi, Rajwa, Pawel, Bianchi, Alberto, Pallauf, Maximilian, Mostafaei, Hadi, Chlosta, Marcin, Pradere, Benjamin, Karakiewicz, Pierre I., Schmidinger, Manuela, Rub, Ronen, and Shariat, Shahrokh F.
- Subjects
RENAL cell carcinoma ,SURVIVAL rate ,NEPHRECTOMY ,SURGICAL margin ,CLINICAL pathology ,RENAL veins - Abstract
Renal cell carcinoma (RCC) represents 2% of all diagnosed malignancies worldwide, with disease recurrence affecting 20% to 40% of patients. Existing prognostic recurrence models based on clinicopathological features continue to be a subject of controversy. In this meta‐analysis, we summarized research findings that explored the correlation between clinicopathological characteristics and post‐surgery survival outcomes in non‐metastatic RCC patients. Our analysis incorporates 99 publications spanning 140 568 patients. The study's main findings indicate that the following clinicopathological characteristics were associated with unfavorable survival outcomes: T stage, tumor grade, tumor size, lymph node involvement, tumor necrosis, sarcomatoid features, positive surgical margins (PSM), lymphovascular invasion (LVI), early recurrence, constitutional symptoms, poor performance status (PS), low hemoglobin level, high body‐mass index (BMI), diabetes mellitus (DM) and hypertension. All of which emerged as predictors for poor recurrence‐free survival (RFS) and cancer‐specific survival. Clear cell (CC) subtype, urinary collecting system invasion (UCSI), capsular penetration, perinephric fat invasion, renal vein invasion (RVI) and increased C‐reactive protein (CRP) were all associated with poor RFS. In contrast, age, sex, tumor laterality, nephrectomy type and approach had no impact on survival outcomes. As part of an additional analysis, we attempted to assess the association between these characteristics and late recurrences (relapses occurring more than 5 years after surgery). Nevertheless, we did not find any prediction capabilities for late disease recurrences among any of the features examined. Our findings highlight the prognostic significance of various clinicopathological characteristics potentially aiding in the identification of high‐risk RCC patients and enhancing the development of more precise prediction models. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Clear Cell Renal Cell Carcinoma with Neovascularization and Ureteral Extension in a 63-Year-Old Female Unravelled by Pelvicalyceal Penetration.
- Author
-
Zafar, Nauman, Nusrat, Nadeem Bin, Bajwa, Sarmad Imtiaz, and Imtiaz, Saira
- Subjects
- *
RENAL cell carcinoma , *NEOVASCULARIZATION , *KIDNEY tumors , *KIDNEY pelvis , *RENAL cancer , *URETER diseases - Abstract
Approximately 3% to 4% of all newly diagnosed cancers are kidney tumours, which can develop from either the renal parenchymal tissue or the renal pelvis. Kidney cancer is one of the 13 most prevalent kinds of malignancy worldwide. 85% of all malignant kidney neoplasms are renal cell carcinomas (RCC). We present a rare instance of an RCC that had a thrombus in the ureter and had directly extended into the renal pelvicalyceal system. A thorough diagnostic workup was required because the patient had a number of symptoms, including flank pain, hematuria, and weight loss. Imaging tests identified a renal parenchymal-derived infiltrative tumour with remarkable pelvicalyceal penetration. Neovascularization was found within the tumour as a result of additional search. The discovery of ureteral extension, a peculiar characteristic, raised questions regarding both local and distant metastases. R.E.N.A.L nephrometry score was 11 with high complexity. Multidisciplinary management of the intricate clinical problem was employed. After removing the tumour mass, the ureteral involvement was treated with surgical resection, adjuvant therapy, and CT monitoring over the three-month high-risk follow-up period. With surgery, targeted treatment was employed to stop the cancer from growing. Conclusion: The importance of identifying unusual RCC presentations and employing a comprehensive diagnostic and treatment strategy is emphasised by this study. The complex interaction of ureteral extension, neovascularization, and pelvicalyceal penetration highlights the aggressiveness of advanced RCC. Since we are not aware of any literature documented instances including this combination, there are few studies explaining pelvicalyceal system invasion that defies commonly recognised diagnostic and treatment paradigms for renal cell carcinoma. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
- Author
-
Qu Le, Associate chief urologist
- Published
- 2023
35. Late-Onset Metastasis of Renal Cell Carcinoma: A Rare Case of Sinonasal Malignancy Post-Nephrectomy
- Author
-
Vashisth, Swati, Gupta, Ayushi, Chaudhary, Ankita, and Aggarwal, Poonam
- Published
- 2024
- Full Text
- View/download PDF
36. PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors
- Author
-
Xu, Xianglai, Wang, Jiahao, Wang, Ying, Zhu, Yanjun, Wang, Jiajun, and Guo, Jianming
- Published
- 2024
- Full Text
- View/download PDF
37. Diagnostic accuracy of the Clear Cell Likelihood Score and selected MRI parameters in the characterization of indeterminate renal masses – a single-institution study
- Author
-
Blachura, Tomasz, Matusik, Patrycja S., Kowal, Aleksander, Radzikowska, Julia, Jarczewski, Jarosław D., Skiba, Łukasz, Popiela, Tadeusz J., and Chrzan, Robert
- Published
- 2024
- Full Text
- View/download PDF
38. Seismic evaluation of existing reinforced cement concrete building and steel–concrete composite building
- Author
-
Patil, Santosh Kalyanrao, Pujari, Atul Bhimrao, Undre, Abhijeet Ravindra, and Jadhav, Vipul Vishnu
- Published
- 2024
- Full Text
- View/download PDF
39. Correlations of SDF-1ɑ and XRCC1 gene polymorphisms with the risk of renal cancer development and bioinformatics studies of SDF-1α and XRCC1 and the prognosis of renal cancer
- Author
-
Wenjing Zhang, Yubo Su, Genquan Yue, Lingyan Zhao, Hailing Li, Min Jia, Yuqi Wang, Dongyang Liu, Haisheng Wang, and Yumin Gao
- Subjects
SDF-1α gene ,XRCC1 gene ,SNP ,RCC ,Bioinformatics analysis ,Medicine ,Science - Abstract
Abstract To study the relationships between stromal cell-derived factor-1 (SDF-1ɑ) and renal cell carcinoma (RCC) susceptibility and the presence of single nucleotide polymorphisms in the human X-ray cross-complementary repair gene (XRCC1). Compare SDF-1 based on RCC related data in the TCGA database α, The expression difference of XRCC1 between RCC tissue and normal tissue; Collect 166 newly diagnosed RCC cases and 166 healthy individuals who underwent physical examinations during the same period, and detect genotype using iMLDR method. The results The rs1801157 locus (C:T) of the SDF-1α gene was not significantly associated with the pathohistological type, the rs1799782 locus (G:A) of the XRCC1 gene was associated with the pathohistological type of RCC, and there were interactions between rs1799782 and smoking, alcohol consumption, pesticide exposure, hair dye, and urine holding. The rs1799782 locus of the XRCC1 gene may be a key factor in the pathogenesis and pathological development of RCC. High SDF-1ɑ expression is a protective factor for the overall survival of patients with RCC, and SDF-1ɑ and XRCC1 may be important for the treatment of RCC.
- Published
- 2024
- Full Text
- View/download PDF
40. Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer
- Author
-
Muhammad Ali, Kendrick Koo, David Chang, Phil Chan, Sheng F. Oon, Daniel Moon, Declan G. Murphy, Renu Eapen, Jeremy Goad, Nathan Lawrentschuk, Arun A. Azad, Sarat Chander, Mark Shaw, Nicholas Hardcastle, and Shankar Siva
- Subjects
Stereotactic ablative radiotherapy ,SABR ,Renal cell carcinoma ,RCC ,Chronic kidney disease ,End-stage renal disease ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Stereotactic ablative body radiotherapy (SABR) is an emerging treatment for patients with primary renal cell carcinoma (RCC). However, its impact on renal function is unclear. This study aimed to evaluate incidence and clinical factors predictive of severe to end-stage chronic kidney disease (CKD) after SABR for RCC. Methods and materials This was a Single institutional retrospective analysis of patients with diagnosed primary RCC receiving SABR between 2012–2020. Adult patients with no metastatic disease, baseline estimated glomerular filtration rate (eGFR) of ≥ 30 ml/min/1.73 m2, and at least one post-SABR eGFR at six months or later were included in this analysis. Patients with upper tract urothelial carcinoma were excluded. Primary outcome was freedom from severe to end-stage CKD, determined using the Kaplan–Meier estimator. The impact of baseline CKD, age, hypertension, diabetes, tumor size and fractionation schedule were assessed by Cox proportional hazard models. Results Seventy-eight consecutive patients were included, with median age of 77.8 years (IQR 70–83), tumor size of 4.5 cm (IQR 3.9–5.8) and follow-up of 42.2 months (IQR 23–60). Baseline median eGFR was 58 mls/min; 55% (n = 43) of patients had baseline CKD stage 3 and the remainder stage 1–2. By last follow-up, 1/35 (2.8%) of baseline CKD 1–2, 7/27 (25.9%) CKD 3a and 11/16 (68.8%) CKD 3b had developed CKD stage 4–5. The estimated probability of freedom from CKD stage 4–5 at 1 and 5 years was 89.6% (CI 83.0–97.6) and 65% (CI 51.4–81.7) respectively. On univariable analysis, worse baseline CKD (p
- Published
- 2024
- Full Text
- View/download PDF
41. Synchronous bilateral papillary renal cell carcinoma in the native kidneys after 10 Years of renal transplantation: Report of a case and review of the literature
- Author
-
Haytham Araibi
- Subjects
RCC ,Native kidneys ,Transplantation ,Papillary RCC ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
A case of synchronous bilateral native kidneys papillary RCC is presented in a 48 year old patient who underwent a living donor kidney transplant 10 years prior. He was on regular immunosuppressant therapy. Despite the long term follow-up, bilateral cystic and exophytic masses were incidentally found on CT scan. Subsequent bilateral open radical nephrectomy revealed papillary RCC in both kidneys.
- Published
- 2024
- Full Text
- View/download PDF
42. Can We Predict Recurrence of pT1-2 Renal Cell Carcinoma?
- Author
-
Üçer, Oktay, Müezzinoğlu, Talha, Aslan, Güven, Süer, Evren, Baltacı, Sümer, İzol, Volkan, Özden, Ender, Akdoğan, Bülent, Yazıcı, Sertaç, Bulut, Ender Cem, Akdoğan, Nebil, and Sözen, Sinan
- Subjects
- *
KIDNEY tumors , *PROGNOSTIC models , *TUMOR classification , *UNIVARIATE analysis , *MULTIVARIATE analysis - Abstract
Objective: Some prognostic models have been described for localized and metastatic renal cell carcinoma (RCC). The European Association of Urology guidelines on RCC recommend using these models. However, there is no model for T1 and T2. The study evaluated the risk factors for recurrence in T1 and T2 RCC. Materials and Methods: Data of 4823 renal tumor patients from the Renal Tumor Database of the Association of Urooncology in Turkey were evaluated. Of 4823 patients, 1845 RCC patients with pathological T1 or T2 were included in this study. The patients were divided into two groups according to the recurrence status. Anatomical, histological, and clinical prognostic factors were statistically compared between the groups. Afterwards, multivariate analysis was performed for the variables that were found to be statistically significant. Results: The mean follow-up time was 30 (4-180) months. Of 1845 RCC patients, 117 (6.3%) had recurrence. Univariate analysis revealed statistically significant differences between age, preoperative hemoglobin, albumin, neutrophil, alkaline phosphates, platelet and calcium values, histological subtype, Fuhrman grade, surgical technique (radical or partial), and pathological stage in the groups. However, in multivariate analysis, only pathological stage was found to be a risk factor for recurrence (2.17 95%, 1.25-3.77). Conclusions: The results of our study show that it is difficult to design a prognostic model for the recurrence of pT1 and pT2 RCC. We suggest that patients with a higher tumor diameter should be followed up more frequently. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Biphasic papillary (biphasic squamoid alveolar) renal cell carcinoma: a clinicopathologic and molecular study of 17 renal cell carcinomas including 10 papillary adenomas.
- Author
-
Nova-Camacho, Luiz M., Acosta, Andres M., Akgul, Mahmut, Panizo, Angel, Galea, Laurence A., Val-Carreres, Andrea, Talavera, Juan A., Guerrero-Setas, David, Martin-Arruti, Maialen, Ruiz, Irune, García-Martos, María, and Sangoi, Ankur R.
- Abstract
Biphasic papillary renal cell carcinoma (synonymous with biphasic squamoid alveolar renal cell carcinoma) is considered within the spectrum of papillary renal cell carcinoma (PRCC). With < 70 reported cases of biphasic PRCC, there is limited data on the pathologic spectrum and clinical course. Seventeen biphasic PRCC cases and 10 papillary adenomas with similar biphasic morphology were assessed. The mean age of the biphasic PRCC patients was 62 years (male to female ratio of 1.8:1), from 10 partial nephrectomies, 6 radical nephrectomies, and 1 biopsy. The mean tumor size was 3.6 cm (range 1.6-8 cm), with 24% showing multifocality. Fifteen out of 17 cases were limited to the kidney (one of which was staged as pT2a but had lung metastases at diagnosis) and 2/17 cases were staged as T3a. All tumors showed typical biphasic morphology with an extent of squamoid foci widely variable from 10 to 95%. Emperipolesis was identified in 88% of cases. All biphasic PRCC tested exhibited positivity for PAX8 (16/16), keratin 7 (17/17), EMA (15/15), AMACR (17/17), and vimentin (12/12) in both large and small cells; cyclin D1 was only expressed in the large cells (16/16). The 10 papillary adenomas showed a similar immunoprofile to biphasic PRCC. NGS testing performed on 13 biphasic PRCC revealed 4 (31%) harboring MET SNVs. In 1/5 (20%) papillary adenomas, a pathogenic MET SNV was identified. Biphasic PRCC is rare with a generally similar immunoprofile to "type 1" PRCC but with notable strong positivity for cyclin D1 in the large cell component. Although most of the biphasic PRCC cases were of small size, low stage, and with an indolent behavior, one patient had metastatic disease and one patient died of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer.
- Author
-
Ali, Muhammad, Koo, Kendrick, Chang, David, Chan, Phil, Oon, Sheng F., Moon, Daniel, Murphy, Declan G., Eapen, Renu, Goad, Jeremy, Lawrentschuk, Nathan, Azad, Arun A., Chander, Sarat, Shaw, Mark, Hardcastle, Nicholas, and Siva, Shankar
- Subjects
- *
RENAL cancer , *STEREOTACTIC radiotherapy , *PROPORTIONAL hazards models , *CHRONIC kidney failure , *RENAL cell carcinoma , *KIDNEY diseases - Abstract
Background: Stereotactic ablative body radiotherapy (SABR) is an emerging treatment for patients with primary renal cell carcinoma (RCC). However, its impact on renal function is unclear. This study aimed to evaluate incidence and clinical factors predictive of severe to end-stage chronic kidney disease (CKD) after SABR for RCC. Methods and materials: This was a Single institutional retrospective analysis of patients with diagnosed primary RCC receiving SABR between 2012–2020. Adult patients with no metastatic disease, baseline estimated glomerular filtration rate (eGFR) of ≥ 30 ml/min/1.73 m2, and at least one post-SABR eGFR at six months or later were included in this analysis. Patients with upper tract urothelial carcinoma were excluded. Primary outcome was freedom from severe to end-stage CKD, determined using the Kaplan–Meier estimator. The impact of baseline CKD, age, hypertension, diabetes, tumor size and fractionation schedule were assessed by Cox proportional hazard models. Results: Seventy-eight consecutive patients were included, with median age of 77.8 years (IQR 70–83), tumor size of 4.5 cm (IQR 3.9–5.8) and follow-up of 42.2 months (IQR 23–60). Baseline median eGFR was 58 mls/min; 55% (n = 43) of patients had baseline CKD stage 3 and the remainder stage 1–2. By last follow-up, 1/35 (2.8%) of baseline CKD 1–2, 7/27 (25.9%) CKD 3a and 11/16 (68.8%) CKD 3b had developed CKD stage 4–5. The estimated probability of freedom from CKD stage 4–5 at 1 and 5 years was 89.6% (CI 83.0–97.6) and 65% (CI 51.4–81.7) respectively. On univariable analysis, worse baseline CKD (p < 0.0001) and multi-fraction SABR (p = 0.005) were predictive for development of stage 4–5 CKD though only the former remained significant in multivariable model. Conclusion: In this elderly cohort with pre-existing renal dysfunction, SABR achieved satisfactory nephron sparing with acceptable rates of severe to end-stage CKD. It can be an attractive option in patients who are medically inoperable. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Correlations of SDF-1ɑ and XRCC1 gene polymorphisms with the risk of renal cancer development and bioinformatics studies of SDF-1α and XRCC1 and the prognosis of renal cancer.
- Author
-
Zhang, Wenjing, Su, Yubo, Yue, Genquan, Zhao, Lingyan, Li, Hailing, Jia, Min, Wang, Yuqi, Liu, Dongyang, Wang, Haisheng, and Gao, Yumin
- Subjects
- *
RENAL cancer , *STROMAL cell-derived factor 1 , *GENETIC polymorphisms , *DISEASE risk factors , *CARCINOGENESIS , *LOCUS (Genetics) - Abstract
To study the relationships between stromal cell-derived factor-1 (SDF-1ɑ) and renal cell carcinoma (RCC) susceptibility and the presence of single nucleotide polymorphisms in the human X-ray cross-complementary repair gene (XRCC1). Compare SDF-1 based on RCC related data in the TCGA database α, The expression difference of XRCC1 between RCC tissue and normal tissue; Collect 166 newly diagnosed RCC cases and 166 healthy individuals who underwent physical examinations during the same period, and detect genotype using iMLDR method. The results The rs1801157 locus (C:T) of the SDF-1α gene was not significantly associated with the pathohistological type, the rs1799782 locus (G:A) of the XRCC1 gene was associated with the pathohistological type of RCC, and there were interactions between rs1799782 and smoking, alcohol consumption, pesticide exposure, hair dye, and urine holding. The rs1799782 locus of the XRCC1 gene may be a key factor in the pathogenesis and pathological development of RCC. High SDF-1ɑ expression is a protective factor for the overall survival of patients with RCC, and SDF-1ɑ and XRCC1 may be important for the treatment of RCC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Localised non‐metastatic sarcomatoid renal cell carcinoma: a 31‐year externally verified study.
- Author
-
Blum, Kyle A., Silagy, Andrew W., Knezevic, Andrea, Weng, Stanley, Wang, Alan, Mano, Roy, Marcon, Julian, DiNatale, Renzo G., Sanchez, Alejandro, Tickoo, Satish, Gupta, Sounak, Motzer, Robert, Haas, Naomi B., Kim, Se Eun, Uzzo, Robert G., Coleman, Jonathan A., Hakimi, A. Ari, and Russo, Paul
- Subjects
- *
RENAL cell carcinoma , *NEPHRECTOMY , *MINIMALLY invasive procedures , *CHI-squared test , *TUMOR classification , *OVERALL survival - Abstract
Objective: To evaluate post‐nephrectomy outcomes and predictors of cancer‐specific survival (CSS) between patients with localised sarcomatoid renal cell carcinoma (sRCC) and those with Grade 4 RCC (non‐sRCC), as most sRCC research focuses on advanced or metastatic disease with limited studies analysing outcomes of patients with localised non‐metastatic sRCC. Patients and Methods: A total of 564 patients with localised RCC underwent partial or radical nephrectomy between June 1988 to March 2019 for sRCC (n = 204) or World Health Organization/International Society of Urological Pathology Grade 4 non‐sRCC (n = 360). The CSS at every stage between groups was assessed. Phase III ASSURE clinical trial data were used to externally validate the CSS findings. The Mann–Whitney U‐test and chi‐squared test compared outcomes and the Kaplan–Meier method evaluated CSS, overall survival (OS) and recurrence‐free survival. Clinicopathological features associated with RCC death were evaluated using Cox proportional hazards regression. Results: The median follow‐up was 31.5 months. The median OS and CSS between the sRCC and Grade 4 non‐sRCC groups was 45 vs 102 months and 49 vs 152 months, respectively (P < 0.001). At every stage, sRCC had worse CSS compared to Grade 4 non‐sRCC. Notably, pT1 sRCC had worse CSS than pT3 Grade 4 non‐sRCC. Negative predictors of CSS were sarcomatoid features, non‐clear cell histology, positive margins, higher stage (pT3/pT4), and use of minimally invasive surgery (MIS). ASSURE external verification showed worse CSS in patients with sRCC (hazard ratio [HR] 1.63, 95% confidence interval [CI] 1.12–2.36; P = 0.01), but not worse outcomes in MIS surgery (HR 1.39, 95% CI 0.75–2.56; P = 0.30). Conclusions: Localised sRCC had worse CSS compared to Grade 4 non‐sRCC at every stage. Negative survival predictors included positive margins, higher pathological stage, use of MIS, and non‐clear cell histology. sRCC is an aggressive variant even at low stages requiring vigilant surveillance and possible inclusion in adjuvant therapy trials. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. The role of [68 Ga]Ga-FAPI-04 PET/CT in renal cell carcinoma: a preliminary study.
- Author
-
Civan, Caner, Kuyumcu, Serkan, Has Simsek, Duygu, Sanli, Oner, Isik, Emine Goknur, Ozkan, Zeynep Gozde, Hurdogan, Ozge, and Sanli, Yasemin
- Subjects
- *
POSITRON emission tomography , *RENAL cell carcinoma , *LUNG diseases - Abstract
Purpose: We aimed to investigate the role of [68 Ga]Ga-FAPI-04 PET/CT and uptake patterns of primary and metastatic lesions in patients with renal cell carcinoma (RCC). Methods: Twenty patients with a suspicious lesion considered primary renal malignancy or a history of RCC were included in our study. Two patients were excluded from further analyses due to other confirmed malignancies. Six patients were newly diagnosed, while the indication of 12 patients was restaging. All patients underwent [68 Ga]Ga-FAPI-04 and [18F]F-FDG PET/CT. SUVmax and tumor-to-background ratio (TBR) of primary (n = 7) and local recurrent lesions (n = 6) and lymph node (n = 26), lung (n = 32), bone (n = 5), and other metastases (n = 14) were compared between the two tracers. Results: We detected 90 lesions in 18 patients with varying FAPI and FDG uptake values on both PET/CT. The median TBR of FAPI-PET/CT of all lesions was higher than TBR of FDG-PET/CT with statistically significance (5.6 vs. 2.1, p < 0.001). In primary and recurrent lesions, the median SUVmax, TBR, and tumor volume on FAPI-PET/CT were higher than FDG-PET/CT. The median SUVmax of lung lesions on FAPI-PET/CT was statistical significantly higher than FDG-SUVmax (3.8 vs. 1.8, p = 0.02). The median of FAPI-SUVmax on primary lesions was lower in the early stage based on TNM compared to the advanced stage. FAPI-SUVmax in 49% of all lesions were SUVmax ≥ 6, and 13% were SUVmax ≥ 10. In patient-based analyses, seven patients (39%) had at least one lesion with FAPI-SUVmax ≥ 10; 12 patients (67%) had at least one lesion with FAPI-SUVmax ≥ 6. Conclusion: This study showed the potential utility of [68 Ga]Ga-FAPI-04 PET/CT showing promising results in RCC. We have presumed that FAPI-PET/CT may be performed for complementary imaging modality providing prognosis and possibility of theranostic application in selected patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Novel Approaches with HIF-2α Targeted Therapies in Metastatic Renal Cell Carcinoma.
- Author
-
Nguyen, Charles B., Oh, Eugene, Bahar, Piroz, Vaishampayan, Ulka N., Else, Tobias, and Alva, Ajjai S.
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *RENAL cell carcinoma , *IMMUNE checkpoint inhibitors , *VON Hippel-Lindau disease , *METASTASIS , *INVESTIGATIONAL drugs , *ANTINEOPLASTIC agents , *DRUG synergism , *TRANSCRIPTION factors , *DRUG resistance in cancer cells , *CHEMICAL inhibitors , *DISEASE complications - Abstract
Simple Summary: Belzutifan, a hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, has emerged as an exciting new treatment option not only for patients with Von Hippel-Lindau (VHL)-related renal cell carcinoma (RCC) but also for sporadic RCC. While initial clinical data are promising, potential resistance with HIF-2α inhibitors may occur with increased understanding of this class of therapy. Potential ways to further increase the antitumor activity of HIF-2α targeting include combination strategies with immune checkpoint inhibitors and other targeted agents as well as newer generation HIF-2α inhibitors that are currently under development. Germline inactivation of the Von Hippel-Lindau (VHL) tumor suppressor is the defining hallmark in hereditary VHL disease and VHL-associated renal cell carcinoma (RCC). However, somatic VHL mutations are also observed in patients with sporadic RCC. Loss of function VHL mutations result in constitutive activation of hypoxia-inducible factor-2 alpha (HIF-2α), which leads to increased expression of HIF target genes that promote angiogenesis and tumor growth. As of 2023, belzutifan is currently the only approved HIF-2α inhibitor for both VHL-associated and sporadic metastatic RCC (mRCC). However, there is potential for resistance with HIF-2α inhibitors which warrants novel HIF-2α-targeting strategies. In this review, we discuss the potential resistance mechanisms with belzutifan and current clinical trials evaluating novel combinations of belzutifan with other targeted therapies and immune checkpoint inhibitors which may enhance the efficacy of HIF-2α targeting. Lastly, we also discuss newer generation HIF-2α inhibitors that are currently under early investigation and outline future directions and challenges with HIF-2α inhibitors for mRCC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Long noncoding RNA: An emerging diagnostic and therapeutic target in kidney diseases.
- Author
-
Ramanathan, Kumaresan, Fekadie, Minale, Padmanabhan, Giri, and Gulilat, Henok
- Subjects
- *
LINCRNA , *KIDNEY diseases , *DIABETIC nephropathies , *IGA glomerulonephritis , *ACUTE kidney failure , *CHRONIC kidney failure - Abstract
Long noncoding RNAs (lncRNAs) have critical roles in the development of many diseases including kidney disease. An increasing number of studies have shown that lncRNAs are involved in kidney development and that their dysregulation can result in distinct disease processes, including acute kidney injury, chronic kidney disease, and renal cell carcinoma. Understanding the roles of lncRNAs in kidney disease may provide new diagnostic and therapeutic opportunities in the clinic. This review provides an overview of lncRNA characteristics, and biological function and discusses specific studies that provide insight into the function and potential application of lncRNAs in kidney disease treatment. Significance Statement: Globally mortality rates from kidney diseases are sharply growing. The diagnosis and treatment of renal diseases are still delays, particularly in the early stages of the condition. It is necessary to develop more novel diagnostic and therapeutic procedures. Many studies conducted recently have connected long noncoding RNAs (lncRNAs) to the pathophysiology of different kidney diseases. In this review, we present an in‐depth analysis of the present biogenesis, degradation, and functions of lncRNAs and highlight the current understanding of their roles in kidney diseases and their complications, such as acute kidney injury, diabetic nephropathy, membranous nephropathy, immunoglobulin A nephropathy, lupus nephritis, and chronic kidney disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Detection of Testicular Metastasis from Renal Cell Carcinoma on PSMA-PET Scan.
- Author
-
Olmstead, Theresa, Emmerling, Michael, Bantumilli, Surekha, Raynor, Mathew, Nielsen, Matthew E., Bjurlin, Marc A., and Rose, Tracy L.
- Subjects
- *
RENAL cell carcinoma , *PROSTATE cancer , *CANCER diagnosis , *METASTASIS , *DIAGNOSIS , *POSITRON emission tomography - Abstract
The use of prostate-specific membrane antigen-positron emission tomography (PSMA-PET) is becoming more widespread for the diagnosis and management of prostate cancer. Here we report a case of oligometastatic renal cell carcinoma (RCC) to the testes diagnosed incidentally on PSMA-PET imaging. This case demonstrates the potential for diagnosis of nonprostate disease with PSMA-PET imaging, as well as the promising nature of PSMA-PET for the diagnosis and surveillance of RCC. In addition, this case report discusses the rare occurrence of oligometastatic RCC to the testis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.